This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research article
A preliminary study on the joint parameter Lym% and HGB for the prediction of severe and nonsevere COVID-19
Jiuxin Qu
Corresponding Author
ORCiD: https://orcid.org/0000-0003-1061-2353
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Objectives
The aim of this study was to identify the parameters in routine blood tests that can be used to evaluate the severity of coronavirus disease 2019 (COVID-19) and thus assist in clinically predicting the extent of progression.
Methods
This study retrospectively analyzed the epidemiological, clinical symptom and laboratory examination data of 159 COVID-19 patients. The percentage of lymphocytes (Lym%) and hemoglobin (HGB) were integrated into a joint parameter, Lym%&HGB, by binary logistic regression.
Results
Both Lym% and HGB gradually decreased with disease progression whereas the joint parameter Lym%&HGB increased gradually with disease progression. When using Lym%, HGB, and Lym%&HGB to predict COVID-19 severity, the area under the receiver operating characteristic (ROC) curve (AUC) was 0.89, 0.79, and 0.92, respectively. The dynamic change curves showed that Lym% and HGB continued to decline while Lym%&HGB continued to increase with disease progression in patients with severe COVID. The change in Lym%&HGB was more prominent than the changes in Lym% and HBG.
Conclusions
The joint parameter Lym%&HGB can serve as a good tool to differentiate severe and nonsevere COVID-19, and it has a higher sensitivity and specificity than either Lym% or HGB alone.
Keywords
2019 novel coronavirus disease (COVID-19), lymphocyte (Lym), hemoglobin (HGB), receiver operating characteristic curve (ROC), severity indicator, dynamic profile
Figure 1
Figure 2
Figure 3
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 12 Jun, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Infectious Diseases
Learn more about our company.
This is a preprint. It has not completed peer review.
Research article
A preliminary study on the joint parameter Lym% and HGB for the prediction of severe and nonsevere COVID-19
Jiuxin Qu
Corresponding Author
ORCiD: https://orcid.org/0000-0003-1061-2353
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 12 Jun, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Infectious Diseases
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Objectives
The aim of this study was to identify the parameters in routine blood tests that can be used to evaluate the severity of coronavirus disease 2019 (COVID-19) and thus assist in clinically predicting the extent of progression.
Methods
This study retrospectively analyzed the epidemiological, clinical symptom and laboratory examination data of 159 COVID-19 patients. The percentage of lymphocytes (Lym%) and hemoglobin (HGB) were integrated into a joint parameter, Lym%&HGB, by binary logistic regression.
Results
Both Lym% and HGB gradually decreased with disease progression whereas the joint parameter Lym%&HGB increased gradually with disease progression. When using Lym%, HGB, and Lym%&HGB to predict COVID-19 severity, the area under the receiver operating characteristic (ROC) curve (AUC) was 0.89, 0.79, and 0.92, respectively. The dynamic change curves showed that Lym% and HGB continued to decline while Lym%&HGB continued to increase with disease progression in patients with severe COVID. The change in Lym%&HGB was more prominent than the changes in Lym% and HBG.
Conclusions
The joint parameter Lym%&HGB can serve as a good tool to differentiate severe and nonsevere COVID-19, and it has a higher sensitivity and specificity than either Lym% or HGB alone.
Figure 1
Figure 2
Figure 3